There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bio-Rad Laboratories (BIO – Research Report), Biogen (BIIB – Research Report) and REPRO-MED Systems (KRMD – Research Report) with bullish sentiments.
Bio-Rad Laboratories (BIO)
Jefferies analyst Brandon Couillard maintained a Buy rating on Bio-Rad Laboratories yesterday and set a price target of $560.00. The company’s shares closed last Wednesday at $314.00.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of
Currently, the analyst consensus on Bio-Rad Laboratories is a Strong Buy with an average price target of $536.50.
See Insiders’ Hot Stocks on TipRanks >>
Biogen (BIIB)
Jefferies analyst Michael Yee maintained a Buy rating on Biogen yesterday and set a price target of $350.00. The company’s shares closed last Wednesday at $263.50.
According to TipRanks.com, Yee is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $325.04 average price target, representing a 21.9% upside. In a report issued on October 4, RBC Capital also maintained a Buy rating on the stock with a $351.00 price target.
REPRO-MED Systems (KRMD)
In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on REPRO-MED Systems. The company’s shares closed last Wednesday at $2.60.
According to TipRanks.com, Nowak ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on REPRO-MED Systems is a Strong Buy with an average price target of $3.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIO:
